Core Viewpoint - The newly listed company Insilico Medicine (03696.HK) has announced a long-term R&D collaboration with the French pharmaceutical company Servier, valued at up to $888 million, marking the first business development (BD) deal in the biopharmaceutical sector since 2026 [1][4]. Group 1: Collaboration Details - The collaboration with Servier will leverage Insilico's AI platform Pharma.AI, focusing on challenging targets in oncology to identify and develop new therapeutic drugs [4]. - Insilico is eligible for an upfront payment of up to $32 million and milestone payments based on R&D progress, while Servier will lead clinical validation and commercialization [5][4]. - Insilico has previously established partnerships with companies like Fosun Pharma, Sanofi, and Eli Lilly, with four oncology projects already licensed to partners [6]. Group 2: Financial Performance - Insilico's revenue primarily comes from licensing agreements, with projected revenues of approximately $30.15 million, $51.18 million, $85.83 million, and $27.46 million for the years 2022 to 2025 [6]. - The company reported losses of $222 million, $212 million, $17.1 million, and $19.2 million for the years 2022 to 2025, although losses are gradually narrowing [10]. - The IPO raised a total of HKD 2.277 billion, making it the highest fundraising biopharmaceutical IPO in Hong Kong for 2025, with a stock price increase of 55.43% within four trading days [8]. Group 3: Market Context and Future Outlook - The AI pharmaceutical sector is still in its early commercialization phase, requiring extensive clinical trials for validation [1][8]. - Insilico aims to balance high R&D investments with revenue generation through strategic partnerships, enhancing its long-term competitiveness while creating stable cash flow [11]. - The overall sentiment in the market regarding AI pharmaceuticals is mixed, with some investors optimistic about future growth while others express concerns over the unclear development pathways [9].

Market Overview - On January 5, 2026, the A-share market experienced a "good start," with major indices such as the Shanghai Composite Index, Shenzhen Component Index, ChiNext Index, and STAR Market Index all showing strong performance. The Shanghai Composite Index closed at 4023.42 points, up 1.38%, with a trading volume of 10,673 billion yuan [1] - The total trading volume for both Shanghai and Shenzhen markets reached 25,463.13 billion yuan, an increase of 5,010.9 billion yuan compared to the previous trading day [1] Sector Performance - The media, pharmaceutical, and other sectors showed strong gains, with notable stocks like Fenglong Co. achieving a seven-day consecutive limit-up [2][6] - Among the industry sectors, media, pharmaceuticals, insurance, electronics, computers, defense, non-ferrous metals, food and beverage, and precious metals had the highest gains. Conversely, sectors such as oil and petrochemicals, banking, and transportation saw declines [3] Individual Stock Performance - A total of 3,959 stocks rose, while 1,111 stocks fell, with 127 stocks hitting the daily limit-up and 13 stocks hitting the limit-down [3] - The top individual stocks with significant net inflows included Shenghong Technology with a net inflow of 2.007 billion yuan, followed by Tianji Co. and Dongfang Fortune with net inflows of 871 million yuan and 726 million yuan, respectively [9][11] Capital Flow - The net capital outflow from the main funds in the Shanghai and Shenzhen markets was 6.298 billion yuan, with the ChiNext seeing a net inflow of 1.497 billion yuan and the STAR Market experiencing a net outflow of 4.263 billion yuan [7] - Among the 31 primary industry sectors, 12 sectors saw net capital inflows, with the non-ferrous metals sector leading with a net inflow of 1.907 billion yuan [7] Institutional Activity - Institutional investors had a net selling of approximately 4.97 billion yuan, with BlueFocus being the top net buy stock at around 186 million yuan [16][18] - The stocks with the highest net selling included Aerospace Development, with a net outflow of 1.649 billion yuan, followed by Xinyi Sheng and Shunhao Co. [13][14]

Market Performance - On January 5, 2026, A-shares opened strong, with all three major indices rising collectively, and the Shanghai Composite Index surpassing the 4000-point mark for the first time in over 30 trading days [1] - By the end of the trading day, the Shanghai Composite Index increased by 1.38% to 4023.42 points, marking a "12 consecutive days" rise; the Shenzhen Component Index and the ChiNext Index rose by 2.24% and 2.85%, closing at 13828.63 points and 3294.55 points respectively [1] - The STAR 50 Index performed notably well, rising by 4.4% to 1403.41 points [1] Sector Performance - The brain engineering sector led the market, with several stocks, including Sanbo Brain Science, Botao Biology, and Daoshi Technology, hitting the 20% daily limit [1] - The insurance sector was active throughout the day, with all major stocks in the sector showing gains [1] - Other sectors with significant gains included fourth-generation semiconductors, medical devices, and AI pharmaceuticals, while sectors such as Hainan, duty-free concepts, and tax refund stores experienced declines [1] Trading Volume - The trading volume for the Shanghai Stock Exchange reached approximately 10,673.34 billion yuan, while the Shenzhen Stock Exchange recorded about 14,790.13 billion yuan, leading to a total trading volume of around 25.5 trillion yuan across both exchanges [1]

如此也意味着，在资本市场的喧嚣背后，全球制药行业正以复杂的心态拥抱AI。一方面，AI在提升早 期药物发现效率方面展现出诱人潜力；另一方面，整个AI制药产业仍处于商业化早期，绝大多数公司 尚未实现盈利，其最终价值需通过漫长且高风险的临床试验来验证。不难发现，英矽智能的案例，恰好 为观察这一矛盾中的产业提供了一个绝佳的切片。 战略互补 对于医药产业而言，此次交易受到关注的一大原因在于，英矽智能与施维雅聚焦于"具有挑战性的靶 点"。 一方面，对施维雅而言，这是一次以可控成本获取前沿探索能力的"外包"式创新。传统药企面对难成药 靶点，常因内部研发投入产出比不确定而却步。通过与AI平台合作，施维雅将前期探索的高风险和不 确定性部分转移，以首付款和里程碑付款为杠杆，撬动AI的计算能力，自身则聚焦于擅长的临床开发 与商业化。这是一种风险分散、效率优化的策略，而非根本性的自我颠覆。 另一方面，对英矽智能来说，此次合作的核心价值在于"平台验证"与"现金流补充"。获得跨国药企的背 书，可显著提升其Pharma.AI平台的市场信誉度。高达 3200 万美元的首付款及近期研发里程碑付款，为 公司提供了宝贵的研发资金。这种"服务换现金 ...

Market Performance - On January 5, 2026, A-shares experienced a strong opening, with all three major indices rising collectively, and the Shanghai Composite Index surpassing the 4000-point mark for the first time in over 30 trading days [1] - By the end of the trading day, the Shanghai Composite Index rose by 1.38% to 4023.42 points, marking a "12 consecutive days" increase; the Shenzhen Component Index and the ChiNext Index increased by 2.24% and 2.85%, closing at 13828.63 points and 3294.55 points respectively [1] - The STAR 50 Index showed remarkable performance, rising by 4.4% to 1403.41 points [1] Sector Performance - The brain engineering sector led the market, with several stocks such as Sanbo Brain Science, Botao Biology, and Daoshi Technology hitting the 20% daily limit [1] - The insurance sector was active throughout the day, with all major stocks in the sector showing positive performance [1] - Other sectors with notable gains included fourth-generation semiconductors, medical devices, and AI pharmaceuticals, while sectors such as Hainan, duty-free concepts, and tax refund stores saw declines [1] Trading Volume - The trading volume for the Shanghai Stock Exchange reached approximately 10,673.34 billion yuan, while the Shenzhen Stock Exchange recorded about 14,790.13 billion yuan, leading to a total trading volume of around 25.5 trillion yuan across both exchanges [1]

中国AI Biotech第一股，来了！ 12月30日，英矽智能正式登陆港股，成为中国首家以生成式人工智能驱动药物研发为核心业务的上市公司，首日高开45%。 这一天，距离英矽智能成立已经过去将近12年的时间，历经行业多轮周期。公司不仅经受住了种种考验，更成长为全球AI制药领域最具代表性的企业之 一。 如今，恰逢生成式AI掀起新一轮技术革命，叠加中国创新药海外BD热潮，作为全球极少数同时具备生成式AI平台、拥有临床阶段管线，并成功达成多笔 高价值对外授权交易的AI Biotech，英矽智能的稀缺价值进一步凸显，值得更多期待。 公司自主研发的核心引擎Pharma.AI平台覆盖从靶点识别、小分子生成、先导化合物优化到临床试验预测的端到端药物研发链条，将候选药物从靶点发现 到临床前候选药物（PCC）确认的时间从传统方法的4.5年缩短至12至18个月。 依托Pharma.AI平台，英矽智能已自主开发出超过20项处于临床或IND申报阶段的创新资产，涵盖纤维化、肿瘤学、免疫学、代谢、抗疼痛等领域，充分 验证了其AI技术在真实药物开发场景中的转化能力。 与此同时，公司已将三项高潜力候选药物授权给国际知名企业，累计最高合约总价值 ...

在全球医药工业向智能化加速转型的进程中，AI制药领域迎来新一轮显著进展。成一项为期多年的研 发合作，协议涉及总金额高达8.88亿美元。双方将聚焦抗肿瘤领域具有挑战性的靶点，共同识别并开发 创新疗法。 根据协议条款，英矽智能(03696)有资格获得最高 3200 万美元的首付款及近期研发里程碑付款，并将依 托其人工智能技术平台，筛选并推进符合既定药物研发和科学标准的潜在候选药物;施维雅则将共同承 担研发成本，并在成功提名具有前景的候选药物后，主导后续的临床验证、监管沟通及相关肿瘤候选药 物在全球范围内的商业化进程。 作为 2026 年生物医药领域 BD的"开年首弹"，这一重磅交易不仅在金额上令人瞩目，更将一个核心议 题推向台前：AI制药是否已跨越漫长的"概念验证"，真正步入规模化"价值实现"的新周期? 包括：与 Exelixis、美纳里尼等公司达成的3项管线授权，总金额最高可达 21亿美元;牵手赛诺菲(总潜在 价值高达 12 亿美元)、礼来(总额逾亿美元)及复星医药（600196）等头部药企，达成AI驱动的药物研发 合作;与诺和诺德、勃林格殷格翰、辉瑞等跨国药企(MNC)达成AI软件对外授权合作。 通过将这种经 ...

Core Insights - The collaboration between Insilico Medicine and Servier, valued at $888 million, marks a significant advancement in the AI-driven pharmaceutical sector, focusing on challenging oncology targets and innovative therapies [1][2] - This partnership highlights the transition of AI in drug development from concept validation to a new cycle of value realization, emphasizing the potential of Insilico's Pharma.AI platform [1][6] Group 1: Partnership Details - The agreement allows Insilico to receive up to $32 million in upfront and milestone payments, leveraging its AI technology to identify and advance drug candidates [1] - Servier will share the R&D costs and lead the clinical validation and commercialization of promising drug candidates globally [1] Group 2: Market Performance - Insilico Medicine's IPO on December 30, 2025, was highly successful, with a subscription rate of approximately 1427 times for the public offering, raising over HKD 328.3 billion [3] - The strong backing from top-tier investors, including Eli Lilly, Tencent, and Temasek, reflects a high consensus on the AI pharmaceutical sector's potential [3] Group 3: Strategic Collaborations - Since 2020, Insilico has established a vast network of global partnerships, achieving multiple AI-driven R&D collaborations and pipeline licenses, with total potential values reaching up to $2.1 billion [4] - Collaborations with major pharmaceutical companies like Sanofi and Eli Lilly further enhance Insilico's capabilities in drug development [4] Group 4: Future Challenges - Despite the promising developments, the true test for AI in drug development will be the clinical trial success rates, as the industry shifts focus from early-stage research to efficacy validation [6] - The upcoming years will be crucial in determining whether AI can effectively disrupt traditional drug development timelines and success rates [6]

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [29]. Core Insights - The report highlights that the national government will continue to support the renewal of medical equipment in 2026, which is expected to drive demand in the medical device sector. The focus is on high-end equipment and companies with significant performance improvements and international expansion, such as Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical [3]. - The report emphasizes the optimization of application conditions and review processes for equipment renewal projects, aiming to lower investment thresholds and enhance support for small and medium-sized enterprises [3]. - The ongoing policy for equipment renewal is anticipated to sustain a favorable bidding environment for medical devices, with a gradual improvement in performance as inventory clears [3]. Summary by Sections Industry Overview - The report discusses the government's announcement on December 30, 2025, regarding large-scale equipment renewal and the inclusion of various sectors, including healthcare, in the support framework for 2026 [3]. - It outlines the measures to improve the application process for equipment renewal, including stricter requirements for equipment depreciation and minimum usage periods [3]. Investment Opportunities - The report suggests focusing on companies that are expected to show significant performance improvements and have a leading international presence in the medical device sector [3]. - Specific companies recommended for investment include Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical, which are well-positioned to benefit from the anticipated demand for high-end medical equipment [3]. Market Performance - The medical sector has experienced a decline, with a reported drop of 2.06% in the last week, ranking 25th among 28 industries [8][18]. - The report notes that the medical device market is under pressure in the short term due to policy impacts, but improvements are expected as companies innovate and expand internationally [5].

Core Insights - The successful IPO of Insilico Medicine (stock code: 3696.HK) on the Hong Kong Stock Exchange marks the largest fundraising in the Hong Kong biopharmaceutical sector this year, highlighting the capital market's recognition of AI-driven drug development [1] - Insilico Medicine's partnership with MediXis (stock code: 688202.SH) has gained new attention and industry imagination, emphasizing the critical role of MediXis as a preclinical research service provider in the AI drug development wave [1] Group 1: AI and CRO Integration - The collaboration between Insilico Medicine and MediXis has transformed the drug development paradigm, with MediXis demonstrating efficient and stable delivery capabilities in various tumor projects, enabling rapid clinical progression of AI-discovered molecules [2] - This partnership represents a deep integration of service procurement and technical processes, with Insilico leveraging its Pharma.AI platform for breakthroughs in target discovery and molecular generation, while MediXis provides comprehensive preclinical services [2] Group 2: Expansion of Services and Capabilities - By mid-2025, MediXis has empowered approximately 588 IND approvals, with projects in collaboration with Insilico serving as successful examples of the "AI-driven development + professional CRO execution" model, enhancing both companies' efficiency and experience in AI drug development [3] - MediXis has expanded its AI drug discovery service platform, exploring new therapies such as PROTAC, ADC, nucleic acid drugs, and cell and gene therapies, showcasing its comprehensive strategic layout and capability evolution [4] Group 3: Industry Leadership and Global Strategy - MediXis has solidified its industry-leading position through systematic capability building, achieving breakthroughs in service granularity, technological foresight, compliance systems, and global expansion [4] - The company has successfully obtained various GLP qualifications and enhanced its competitiveness in international preclinical research, with a growing proportion of revenue from overseas clients and increased new order amounts [5] Group 4: Future Outlook - The successful listing of Insilico Medicine signifies a milestone in the capitalization and industrialization of AI drug development, positioning MediXis as an indispensable verification and efficiency engine within the AI drug development ecosystem [6] - As the demand for high-efficiency and high-reliability preclinical research services continues to grow, MediXis is well-positioned to strengthen its leading role as a preclinical research enabler by deepening collaborations with cutting-edge technology companies like Insilico [6]